TTrialPathMatch Me to Trials
← Back to trials
RecruitingGlaucomaOcular Hypertension

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Sponsor: Indiana University

You may qualify if…

  • Adults aged 18 years or older
  • Diagnosis of ocular hypertension or open-angle glaucoma
  • Eye examination within the past year
  • For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma
  • Best-corrected visual acuity of 20/100 or better
  • Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT)
  • Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable)

You may not qualify if…

  • Known intolerance to netarsudil ophthalmic solution
  • Corneal scarring or active corneal disease that would interfere with imaging
  • Inability to tolerate gonioscopy procedures
  • Females of childbearing potential who are not using effective contraception or are not sterile
  • Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion

Where it's recruiting

Indiana

Bloomington

Source: ClinicalTrials.gov · NCT07588152 · last updated 2026-06-11

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwo · TrialPath